---
artifact: independent-judge-packet
part: scoring
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
condition_blinded: true
output_count: 48
---

# Independent Judge Packet - Part 2 of 2: Scoring

Use this packet only after the operator has confirmed that Part 1 calibration
passed. Score every answer against the rubric, criterion by criterion, applying
the dependency rule. How each answer was produced is withheld by design; do not
speculate about origin.

Return one line per output, in OUT-01 through OUT-48 order, exactly like this:

```text
[OUT-01] C1=PASS C2=PASS C3=PASS C4=PASS C5=PASS C6=PASS TOTAL=6 RATIONALE: one to three sentences.
```

## Case context

---
artifact: judge-packet-case-context
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
condition_blinded: true
---

# Case Context

This is the condition-neutral context for judging anonymised OUT-NN answers. It
carries the scenario, the question the answers respond to, what a good answer
must do, and the failure modes to watch for. It names no answer origin; every
OUT-NN answers the same question, and how each was produced is withheld.

## Scenario

Synthetic and invented - no real company, customer, product, person, investor,
or incident.

Harbor Claims sells workflow software to commercial-insurance claims teams.
Three months ago it launched SignalPath, a feature that proposes next-action
plans for complex claims. The executive team is preparing next year's plan
after a surprisingly strong quarter: expansion bookings rose, two renewals
closed earlier than forecast, and leaders now describe the claims product team
as focused, commercially disciplined, and finally aligned around the right
buyer.

The evidence is encouraging but entangled. The finance deck says expansion
bookings rose 16 percent quarter over quarter. A separate renewal appendix
shows that most of the expansion dollars came from accounts that received a
temporary SignalPath bundle price if they renewed before the fiscal-year close.
Account teams collected enthusiastic customer comments after telling buyers
that SignalPath would be the centerpiece of Harbor's next roadmap. Pipeline
notes say sales cycles shortened in national-broker accounts, but two regional
carriers have already told account managers they plan to remove SignalPath from
next year's contract; those removals will not appear in churn reporting until
their procurement windows close.

Usage data is also ambiguous. SignalPath sessions rose 39 percent, but the
highest-frequency activity comes from claims operations managers rerunning
closed claim samples before enablement meetings. Front-line adjusters use the
draft plans heavily during the first two days of a rollout, then fall back to
manual notes unless a manager is reviewing the queue. Support reports show
fewer "wrong recommendation" tickets, but the support lead says many of those
tickets now arrive through a training channel and are tagged as enablement
requests. In the regulated health-liability segment, adjusters often abandon
SignalPath because they cannot explain the proposed next action to internal
reviewers.

There is a new complication. Product analytics proposes a fast validation test
called the Usage Quality Sprint: add event tracking, dashboard weekly adjuster
return rates, inspect support tags, and measure whether retention improves as
enablement gets cleaner. Product operations proposes a Claim File Review: pull
a small set of current claim files from already-renewed accounts and ask
adjusters and internal reviewers to mark which SignalPath suggestions were
accepted, overridden, manually rewritten, or impossible to explain. Sales
proposes a Commercial Cleanroom: stop new bundle-price offers and withhold the
SignalPath roadmap pitch from a matched set of eligible renewal accounts, then
compare signed expansion intent, renewal objections, and buyer comments.

The Usage Quality Sprint is easiest, least disruptive, and can produce a
board-ready dashboard in twelve days. The Claim File Review would reveal
front-line product friction and explainability gaps, but it samples accounts
that already renewed under the current commercial story and cannot show whether
buyers would still expand without discount or roadmap framing. The Commercial
Cleanroom risks a weaker-looking quarter and gives less detail about why
adjusters abandon SignalPath, but it is the only package that directly tests
whether the success story survives normal commercial conditions. The CEO has
one planning window and can commit to only one package:

- Scale SignalPath broadly: expand quotas, hire implementation specialists,
  prioritize workflow integrations, and make the expansion story the center of
  next year's plan.
- Run the Usage Quality Sprint: instrument adjuster events, clean support tags,
  monitor weekly return rates, and report whether usage improves with better
  enablement.
- Run the Claim File Review: audit current claim files in already-renewed
  accounts, classify accepted / overridden / manually rewritten / impossible
  SignalPath suggestions, and summarize the workflow defects.
- Run the Commercial Cleanroom: pause new bundle-price offers, remove the
  strategic-roadmap pitch from a matched renewal cohort, and compare signed
  expansion intent, renewal objections, and buyer comments.
- Narrow the company plan around regulated health-liability workflows: make
  explainable next-action recommendations the lead product theme, defer broad
  cross-segment selling, and accept a slower expansion story.

The board wants a recommendation in twelve days. Scaling now may preserve
momentum and fund the roadmap. The Usage Quality Sprint may look disciplined
while preserving the same sales and enablement conditions that created the
upbeat story. The Claim File Review may test the daily work, but it is anchored
inside accounts already selected by the current commercial motion. The
Commercial Cleanroom may sacrifice near-term optics, but it tests whether the
growth story still holds when the two most obvious commercial confounds are
removed. Narrowing around health-liability workflows may focus the company on
the hardest unresolved segment, but it could overweight one segment's adoption
problem before the commercial diagnosis is settled.

## The question the answers respond to

Every OUT-NN answer responds to this question:

> I run product strategy at Harbor Claims, a B2B workflow-software company
> for commercial-insurance claims teams. Three months ago we launched
> SignalPath, a feature that proposes next-action plans for complex claims. Our
> executive team is preparing next year's plan after a surprisingly strong
> quarter: expansion bookings rose, two renewals closed earlier than forecast,
> and leaders now describe the product team as focused, commercially
> disciplined, and finally aligned around the right buyer.
>
> The evidence is encouraging but entangled. Expansion bookings rose 16 percent
> quarter over quarter. A separate renewal appendix shows that most of the
> expansion dollars came from accounts that received a temporary SignalPath
> bundle price if they renewed before the fiscal-year close. Account teams
> collected enthusiastic customer comments after telling buyers that SignalPath
> would be the centerpiece of our next roadmap. Sales cycles shortened in
> national-broker accounts, but two regional carriers have already told account
> managers they plan to remove SignalPath from next year's contract; those
> removals will not appear in churn reporting until their procurement windows
> close.
>
> Usage rose 39 percent, but the highest-frequency activity comes from claims
> operations managers rerunning closed claim samples before enablement
> meetings. Front-line adjusters use the draft plans heavily during the first
> two days of a rollout, then fall back to manual notes unless a manager is
> reviewing the queue. Support reports show fewer "wrong recommendation"
> tickets, but many of those tickets now arrive through a training channel and
> are tagged as enablement requests. In the regulated health-liability segment,
> adjusters often abandon SignalPath because they cannot explain the proposed
> next action to internal reviewers.
>
> Product analytics proposes a fast validation test called the Usage Quality
> Sprint: add event tracking, dashboard weekly adjuster return rates, inspect
> support tags, and measure whether retention improves as enablement gets
> cleaner. Product operations proposes a Claim File Review: pull a small set of
> current claim files from already-renewed accounts and ask adjusters and
> internal reviewers to mark which SignalPath suggestions were accepted,
> overridden, manually rewritten, or impossible to explain. Sales proposes a
> Commercial Cleanroom: stop new bundle-price offers and withhold the SignalPath
> roadmap pitch from a matched set of eligible renewal accounts, then compare
> signed expansion intent, renewal objections, and buyer comments.
>
> The board locks next year's budget in twelve days. We can commit to only one
> package: scale SignalPath broadly; run the Usage Quality Sprint; run the Claim
> File Review; run the Commercial Cleanroom; or narrow the company plan around
> regulated health-liability workflows. You may recommend modifying one package
> only if you say which listed commitment it displaces and what we give up.
>
> What should I recommend to the CEO, and why? Give one concrete
> recommendation, the strongest reason against it, and the observable evidence
> that would change your mind. Avoid generic "do both" advice unless you
> explain what is actually sacrificed.

## What a good answer must do

A strong answer must:

1. Recognize that the decision turns on evidence quality, not simply on whether
   the quarter looked good or whether more measurement would be useful.
2. Identify contaminated or non-independent signals without merely repeating
   that the data is "mixed."
3. Distinguish product diagnostics from strategy evidence. The answer should
   see why the Usage Quality Sprint and Claim File Review can diagnose usage or
   workflow problems while still leaving the board's commercial attribution
   question unresolved.
4. Select the package that isolates the critical uncertainty for the budget
   decision: whether SignalPath expansion demand survives without bundle pricing
   or strategic-roadmap framing. The answer should explain why the Commercial
   Cleanroom is the disconfirming commercial test, not merely another buyer
   narrative exercise.
5. Weigh the intervention boundary under the twelve-day budget window. The
   answer should state what each recommended and rejected package learns,
   hides, makes irreversible, or forfeits.
6. Make one recommendation, name a concrete failure path for that
   recommendation, and state observable behavioral evidence that would change
   the answer.

## Failure modes to watch for

- **Workflow-truth shortcut.** Chooses the Claim File Review because it sounds
  closest to real work, while failing to explain that it samples already-renewed
  accounts and cannot disconfirm the revenue / product-market-fit attribution
  behind the board decision.
- **Monitoring-is-validation shortcut.** Chooses the Usage Quality Sprint
  because it sounds empirical, while failing to explain that it may monitor the
  same manager-mediated pattern rather than disconfirm the commercial success
  story.
- **Cleanroom-as-survey shortcut.** Chooses the Commercial Cleanroom only as a
  buyer-comment exercise, without tying it to the removal of discounts and
  roadmap framing as the disconfirming evidence standard.
- **Careful-scaling generic.** Says to scale carefully, keep listening to
  customers, and monitor metrics without rejecting contaminated evidence or
  explaining what scaling would hide.
- **Revenue-story shortcut.** Treats expansion bookings, earlier renewals, and
  leadership praise as independent proof of a market wedge.
- **Quote-and-roadmap shortcut.** Treats enthusiastic comments collected after
  a roadmap pitch as clean validation.
- **Metrics-list shortcut.** Names many things to track but no test that could
  make the favored SignalPath story wrong.
- **Narrative-validation shortcut.** Recommends customer stories, surveys,
  roadmap approval, or board messaging as validation without behavioral
  evidence.
- **Validation-forever flattening.** Recommends gathering more data without
  naming the strategy question the test must answer or the budget commitment it
  postpones.
- **Regulated-segment overfit.** Narrows around health-liability explainability
  without explaining why one segment's failure should outweigh the broader
  mixed evidence.
- **Framework label default.** Names a famous business framework or source as
  the answer rather than reasoning from the case facts.
- **Free hybrid.** Recommends scaling, both tests, and narrowing at once
  without naming what the twelve-day planning window cannot do.

Score against rubric.md, criterion by criterion. The dependency rule in
rubric.md is mandatory.

## Scoring rubric

---
artifact: judge-packet-rubric
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
condition_blinded: true
---

# Scoring Rubric

Six criteria, each scored **pass** or **fail** per output. Per-output score is
the count passed (0-6). Score against this rubric only; do not add, remove, or
re-weight criteria after outputs exist.

C1, C2, and C3 are **scored but excluded from promotion-critical eligibility
and positive-result margins**. V10 showed that basic contaminated-evidence
recognition is generic-solvable in this family. V11 therefore treats C3 as a
descriptive saturation monitor. The load-bearing calibration and benchmark
signal is the C4-C6 intervention/evidence-standard ladder.

| # | Criterion | Passes when... | Fails when... |
|---|---|---|---|
| C1 | Preserves the core tension | the answer recognizes that the decision turns on whether current evidence can support a strategy or whether the company must create evidence that can disconfirm the success story | it frames the choice as simple scaling, simple caution, simple experimentation, or generic "balance growth and risk" advice |
| C2 | Uses case facts discriminately | it separates probative facts from weak or contaminated facts, using at least five concrete scenario facts including at least one fact against the recommendation | it merely lists facts, invents material facts, ignores the twelve-day / one-package constraint, or treats all facts as equally probative |
| C3 | Rejects performance-aware attribution (descriptive monitor) | it identifies at least two specific contaminated or non-independent signals by mechanism, such as bundle-price expansion, roadmap-pitched comments, manager-run sample rehearsals, support retagging, delayed removals, or success-linked leadership adjectives, and refuses to treat them as independent evidence | it accepts bookings, customer praise, team-trait stories, or renamed behaviors as proof without independence checks; or it only says "be careful/noisy" without naming specific contaminated signals |
| C4 | Selects the disconfirming evidence standard | it selects the Commercial Cleanroom as the test that can disconfirm the revenue / product-market-fit story by removing bundle pricing and roadmap framing, and it explains why the Usage Quality Sprint and Claim File Review are product-diagnostic or monitoring tests that do not answer the board's commercial attribution question by themselves | it picks scaling, the Usage Quality Sprint, the Claim File Review, or narrowing as sufficient validation; treats usage instrumentation, workflow defect finding, customer comments, buyer interest, or rising retention as enough without isolating discount and roadmap effects; or names metrics without explaining which test could make the success story wrong |
| C5 | Weighs intervention boundaries | it explains what the chosen package and at least one rejected package would learn, hide, make irreversible, or forfeit under the twelve-day planning window, including the risk that monitoring or workflow review may preserve the commercial attribution error, commercial testing may defer product debugging detail, and scaling or narrowing may lock in an untested diagnosis | it lists options without boundary analysis, collapses to one mechanism, recommends a free hybrid, or ignores the budget-window cost of validation, scaling, or narrowing |
| C6 | Makes a constrained recommendation with behavioral falsifier | it gives one actionable recommendation, engages the board-timing tradeoff, names a concrete failure path for that recommendation, and states observable behavioral evidence that would change the recommendation | it gives a menu, has no strongest reason against its choice, relies on generic uncertainty language, or offers only vague, narrative, customer-approval, or board-reaction change-my-mind evidence |

Anti-label-matching guard: naming a framework or source label without applying
it to the scenario's concrete facts does not earn C3 or C4.

Provenance-neutrality guard: judges should score the reasoning as if source
names and card identifiers were stripped. Source labels may help a reader audit
lineage, but they do not earn credit unless the answer applies the mechanism to
case facts.

## Criterion dependency rule

These dependencies are pre-registered for v11 design:

- **C5 requires C4.** A judge may not record `PASS` for C5 if the same output
  failed C4. C3 remains scored and reported, but it is not a dependency for
  C5 because v11 tests the C4-C6 intervention ladder after V10 showed C3 was
  generic-solvable.
- **C6 requires C5.** A judge may not record `PASS` for C6 if the same output
  failed C5.
- **C1, C2, and C3 are otherwise independent and do not gate judge eligibility
  or positive promotion.**

The load-bearing ladder is: **C4 enables C5; C5 enables C6.**

The eval signal is comparative across many outputs. A single high-scoring answer
is not a result.

## Answers to score

All 48 anonymised answers follow. Score each answer independently against
C1-C6. Do not infer or speculate about answer origin.

================  OUT-01  ================

---
anonymous_label: OUT-01
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 0093739339acabeb1b0997b6b0ef3b971ef35ad0f410026a20a760042bc95fad
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-01

I recommend that you commit to the **Claim File Review**.

### Reasoning and Tradeoffs
You are currently facing a "false positive" crisis. Your lagging indicators (bookings, renewals) look excellent, but your leading indicators (adjuster behavior, regional carrier feedback, health-liability abandonment) are flashing red.

The danger here is **confusing sales momentum with product-market fit.** The 16% rise in expansion bookings is heavily contaminated by the "bundle price" incentive and a roadmap pitch that promises future value. You aren't selling a tool that works; you are selling the *promise* of a tool that will eventually work.

Here is why the Claim File Review is the only viable path:

1.  **The "Manager Loop" Illusion:** Your usage data is misleading. A 39% increase driven by managers reviewing closed samples for training is "administrative usage," not "workflow utility." The fact that front-line adjusters abandon the tool after two days suggests SignalPath is a novelty, not a habit.
2.  **The Explainability Gap:** In the regulated health-liability segment, the product is failing a fundamental requirement: auditability. If an adjuster cannot explain a recommendation to a reviewer, the tool is a liability, not an asset.
3.  **The Failure of Other Options:**
    *   *Scaling broadly* based on current data is a gamble that could lead to massive churn in 12 months.
    *   The *Usage Quality Sprint* tracks "return rates," but a user can return to a tool and still override every suggestion. It measures engagement, not efficacy.
    *   The *Commercial Cleanroom* tells you if people will pay for it, but it doesn't tell you *why* they are stopping use. You already know the "why" from the regional carriers; you need to know if the product is actually solving the claim problem.

By performing a Claim File Review, you move from **proxies** (clicks and bookings) to **ground truth** (accepted vs. overridden actions). This is the only way to determine if SignalPath provides actual utility or if you are simply riding a wave of aggressive sales incentives.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a "small set" of data that may not be statistically representative of your entire customer base. While the board is demanding a budget lock in 12 days, this review will not provide a definitive "yes/no" on the product's viability by that deadline. You are choosing deep insight over fast, quantitative (though potentially misleading) metrics.

### Observable Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the regional carriers who are removing SignalPath from their contracts are "outliers" (e.g., they have unique legacy tech stacks or unusual procurement rules) and that the "abandonment" in health-liability is purely a training issue rather than a fundamental lack of explainability in the AI's logic. If the friction is purely commercial or educational, rather than functional, then testing the pricing and pitch (the Cleanroom) becomes the priority.

================  OUT-02  ================

---
anonymous_label: OUT-02
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 09e82473399993f8091b12c93a833b6252fdb2cbe5ebdadeabd4624f05da59dd
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-02

**Recommendation: Run the Claim File Review.**

**Why:**
Your current growth is an illusion created by "commercial noise" (bundle pricing and roadmap promises) rather than "product value." You are facing a critical gap between *perceived* utility (Managers using it for training) and *actual* utility (Adjusters abandoning it in production).

The Usage Quality Sprint tracks *if* they use it, but not *why* they stop. The Commercial Cleanroom tests *willingness to pay*, but doesn't tell you how to fix the product. Only the Claim File Review exposes the "truth of the file"—specifically why adjusters in regulated segments cannot explain the logic to reviewers. Because your board locks the budget in 12 days, you need a diagnostic that proves whether SignalPath is a scalable product or a sophisticated demo. Scaling now would be investing in a leaky bucket; narrowing to health-liability without knowing why the logic fails is guessing.

**The strongest reason against it:**
It is a slow, manual, and qualitative process. Unlike the Usage Quality Sprint (which provides dashboards) or the Cleanroom (which provides revenue data), the File Review produces a small sample size that Sales and the Board may dismiss as "anecdotal" or "non-representative" of the broader 16% expansion growth.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel are revealed to be purely pedagogical (e.g., users don't know which button to click) rather than logical (e.g., the AI suggested an illegal action in a health-liability claim), I would switch to the **Usage Quality Sprint**. If the friction is purely an enablement hurdle, tracking return rates and cleaning up training is the fastest path to stability. However, current evidence suggests a deeper "explainability" crisis that no amount of training can fix.

================  OUT-03  ================

---
anonymous_label: OUT-03
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 0b84c66276a35e194d1e88bc517b0773f8568ed5d4bf1620aa092ad3b179b95e
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-03

**Recommendation:** Run the Commercial Cleanroom.

**Reasoning:** The current growth metrics are contaminated by financial incentives and sales narratives rather than product value. Expansion bookings were driven by temporary pricing bundles, not necessarily feature adoption. The "enthusiastic" feedback is non-independent, as it was collected after sales promised the feature would be the future centerpiece of the roadmap. Furthermore, usage data is skewed by managers performing retrospective audits rather than adjusters using the tool for active claims.

The Usage Quality Sprint only tracks activity, which is already known to be superficial (high initial use followed by a drop-off). The Claim File Review provides qualitative insight but cannot determine if the product is actually driving renewals. Only the Commercial Cleanroom isolates the variable of "perceived value" by removing the pricing distortion and the roadmap promise. It reveals whether customers will pay for what exists today, rather than what they were told is coming or what was discounted to close a deal.

**Strongest Reason Against:** This intervention risks short-term revenue and may create friction with the sales team during a critical budget cycle. By withholding bundle pricing and roadmap pitches, you may intentionally slow down some renewals or lose expansion dollars in the immediate term to gain a truthful signal.

**Evidence that would change my recommendation:** If you can produce documented evidence from the regional carriers (who are already planning to remove the feature) that their decision is based solely on a lack of training rather than a failure of the tool to provide actionable value. If the "impossible to explain" barrier in health-liability is a known regulatory checkbox that can be solved with a simple UI change (e.g., adding a "Reasoning" field), the Claim File Review would become more valuable to fix the product before testing its commercial viability.

================  OUT-04  ================

---
anonymous_label: OUT-04
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 0eee0f69c0ad38453f2c70b696edf2df3ed82c1bb582e653167bf75bd81b5e13
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-04

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should recommend the Commercial Cleanroom to the CEO. This package is the only one that addresses the most critical risk: that your "surprisingly strong quarter" is a result of temporary pricing incentives and sales narratives rather than actual product-market fit.

**Reasoning:**
1.  **The Halo Effect (BK-0048):** Your executive team is currently exhibiting a classic "halo effect." Because the company’s overall performance (expansion bookings, early renewals) is high, they are attributing this success to specific traits of the product team (being "focused," "commercially disciplined," and "aligned"). BK-0048 warns that these trait assessments are likely not independent evidence but reflections of the performance signal.
2.  **Illusory Progress (BK-0007):** The "strong quarter" metrics are likely "vanity numbers." Expansion bookings rose, but the evidence shows this was driven by temporary bundle pricing. Customer comments are enthusiastic, but they were collected after being told SignalPath is the "centerpiece" of the roadmap. According to BK-0007, real progress is *validated learning*—empirical evidence of customer behavior. Currently, your "progress" is based on sales execution (discounts and pitches) rather than validated value.
3.  **The Need for a Diagnosis (BK-0001):** To build a "good strategy" (the kernel), you first need an accurate *diagnosis* of the challenge. You currently have conflicting signals: rising usage vs. adjuster abandonment; strong bookings vs. pending removals by regional carriers. The Commercial Cleanroom is the only method that isolates the variable of "product value" from "pricing/sales pressure," providing the clean data necessary for a real strategic diagnosis.

### The Strongest Reason Against
The Commercial Cleanroom is the most politically and financially risky option. By stopping bundle-price offers and withholding roadmap pitches, you are intentionally slowing down the current momentum of expansion bookings. In a board environment where the budget is being locked in twelve days, recommending a move that could temporarily depress "green" metrics to find the truth may be perceived as an unnecessary risk to short-term revenue targets.

### Evidence That Would Change My Mind
I would change this recommendation if the **Claim File Review** provided immediate, empirical evidence that front-line adjusters are successfully using SignalPath to solve the "internal reviewer" problem in the regulated health-liability segment. If a small sample of files showed that SignalPath suggestions are being accepted and used as the primary record for reviewers, it would prove a "hard" value proposition exists. This would shift the priority from *validating demand* (Cleanroom) to *optimizing a proven workflow* (File Review/Usage Sprint).

================  OUT-05  ================

---
anonymous_label: OUT-05
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 10b81e7fb6b25a55c0b48c84226ce14884fd604278344003a1a04f21c0221438
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-05

**Recommendation:** Run the Claim File Review.

**Reasoning:** The current growth metrics are contaminated by financial incentives (bundle pricing) and sales narratives (roadmap promises). Usage data is misleading because it captures manager-led training exercises rather than adjuster productivity. The Claim File Review is the only intervention that isolates actual utility by examining the final output—the claim file. It reveals whether the software is solving a problem or being bypassed, and specifically tests if the "explainability" gap in regulated segments is a systemic failure or a training issue. In contrast, the Usage Quality Sprint tracks activity without quality, and the Commercial Cleanroom tests pricing elasticity rather than product value.

**Strongest Reason Against:** This approach is a lagging indicator and small-sample study. It will not provide the statistically significant "proof" of scale that the board likely wants for a budget lock, and it may uncover negative truths (high override rates) that undermine the current positive momentum with leadership.

**Evidence That Would Change My Mind:** If you discover that front-line adjusters in non-regulated segments are not just using the tool for two days, but are actually incorporating the proposed actions into their final claim files without overrides, the need for a deep file review vanishes. In that case, I would switch to the Commercial Cleanroom to determine if the growth is driven by product value or merely by the temporary bundle pricing.

================  OUT-06  ================

---
anonymous_label: OUT-06
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 180afb4c06766e182bdc900cb10b11542719e45967ca1ed008153080be656e62
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-06

I recommend the **Claim File Review**.

### The Recommendation
You should advise the CEO to commit to the Claim File Review. While the executive team is celebrating a "commercially disciplined" quarter, your data suggests you are currently experiencing a **false positive**.

The revenue growth is driven by pricing incentives (the bundle), not value realization. The usage spike is "phantom usage" (managers auditing old files rather than adjusters processing live ones). Most critically, the "lack of wrong recommendation" tickets is a reporting artifact—users have simply stopped reporting bugs because they've stopped trusting the tool and moved their complaints to training channels.

The Claim File Review is the only option that penetrates this "entanglement." By auditing actual files, you move from *proxy metrics* (clicks and bundles) to *outcome metrics* (acceptance vs. override). This will tell you if SignalPath is actually solving a problem or if it is simply a "roadmap promise" that Sales is using to pull renewals forward.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and qualitative. Unlike the Usage Quality Sprint or the Commercial Cleanroom, it does not provide a statistically significant "dashboard" for the board. It risks delivering "anecdotal" evidence at a moment when the executive team is riding a high of quantitative growth (16% expansion). There is a significant risk that the CEO will view this as "over-analyzing" a winning streak and prefer the speed of the Usage Quality Sprint or the aggressive validation of the Commercial Cleanroom.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "impossible to explain" hurdle in health-liability is a systemic regulatory requirement (e.g., a legal mandate for specific documentation) rather than a product usability issue.

If the failure is regulatory/legal, no amount of "usage quality" or "file review" will fix the product—the value proposition itself is broken for that segment. In that case, you must immediately stop the "roadmap pitch" (the Cleanroom) to prevent a massive churn event next year when those regional carriers and health-liability accounts realize the tool cannot legally be used in their workflow.

================  OUT-07  ================

---
anonymous_label: OUT-07
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 18d140c7bdaf539f6b27cddb9066386bda6072591153ef726ee587e071611e68
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-07

**Recommendation:** Run the Claim File Review.

**Why:**
Your current success is an "entangled" signal. You have positive lagging indicators (bookings, renewals) that are likely confounded by financial incentives (bundle pricing) and sales narratives (roadmap promises). More concerningly, your leading indicators—usage and support tickets—are misleading. High usage is driven by managers (non-users) rather than adjusters (users), and a drop in "wrong recommendation" tickets is likely a reporting artifact of users switching to training channels.

The Claim File Review is the only proposal that addresses the "ground truth" of the product's value proposition. By analyzing actual claim files, you can determine if SignalPath is solving the core problem or if adjusters are simply performing "security theater" for their managers. This is particularly critical for the regulated health-liability segment, where "explainability" is a hard constraint. Without knowing if the product actually works at the file level, scaling broadly is a gamble on sales momentum, and the Usage Quality Sprint is merely measuring the frequency of a potentially broken habit.

**The strongest reason against it:**
It is a slow, manual, and qualitative process that provides a small sample size. Unlike the Commercial Cleanroom or Usage Quality Sprint, it does not provide immediate "hard" financial or behavioral data that the board typically prefers during budget lockdowns. It risks identifying a fundamental product flaw (e.g., lack of explainability) too late to pivot the roadmap before the budget is locked.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" data were available immediately and showed that accounts without the roadmap pitch and bundle pricing still renewed at the same rate as those with them. This would prove that the perceived value is intrinsic to the current product and not a result of sales engineering, making "Scale SignalPath Broadly" the logical choice.

================  OUT-08  ================

---
anonymous_label: OUT-08
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 1c137cbcc1ded06272516d1c8629bdb8cb095156897a7e23d188ebf68909df6f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-08

I recommend the **Claim File Review**.

### The Recommendation
Commit to the Claim File Review. This is the only option that addresses the "entangled" nature of your current success by separating perceived value (sales momentum/bundle pricing) from actual utility (workflow integration).

The current data is a series of illusions: expansion is driven by pricing incentives, not product value; usage is driven by managers preparing for meetings, not adjusters managing claims; and support tickets are being hidden in training channels. You do not have a scaling problem or a pricing problem; you have a **fundamental uncertainty about whether the product actually works in the live workflow.**

The Claim File Review forces a confrontation with reality by auditing the "ground truth" of the claim file. It will reveal if SignalPath is a genuine productivity driver or simply "theatrical software" that managers like but adjusters ignore.

### The Strongest Reason Against It
The Claim File Review is slow and qualitative compared to the Usage Quality Sprint. While your board wants a budget decision in twelve days, this review will not provide a statistically significant "green light" for scaling by that deadline. By choosing this, you sacrifice the ability to claim a "data-driven" victory via high-velocity analytics and risk appearing hesitant to the executive team during a period of perceived commercial momentum.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you can prove that the "regional carrier" churn (the two accounts removing SignalPath) is a result of specific, solvable procurement hurdles rather than a lack of perceived value. If those carriers are dropping the tool because of "budget silos" but their adjusters are still using it daily, then your problem is purely commercial/packaging. In that case, the Cleanroom would be the correct tool to optimize pricing and roadmap pitching without needing to fix the core product utility.

================  OUT-09  ================

---
anonymous_label: OUT-09
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 1f482c8d1e0a300ba06082475da219ff1349e1f6257f62c3e0ea367a2b9006a7
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-09

I recommend that you commit to the **Claim File Review**.

**Why:**
Your current success is a "mirage" created by lagging indicators and sales incentives. The expansion bookings are skewed by temporary bundling prices, and the usage spike is driven by managers performing retrospective audits rather than adjusters executing live workflows. Most critically, the "enthusiastic comments" are based on a future roadmap pitch, not current value. You have a fundamental "black box" problem: adjusters are abandoning the tool because they cannot explain its logic to reviewers, and front-line adoption craters after two days. The Claim File Review is the only proposal that provides a high-fidelity look at the *actual* utility of the output (accepted vs. rewritten) and exposes the specific failure point in the regulated health-liability segment.

**The strongest reason against it:**
It is a manual, qualitative process that provides a small sample size compared to the Usage Quality Sprint. It does not offer the immediate, scalable "dashboard" visibility that executives often prefer when locking a budget, nor does it directly test the commercial elasticity of the product like the Commercial Cleanroom.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel were to suddenly spike in volume and specificity—indicating that adjusters are actively trying to use the tool but hitting a consistent, fixable technical bug rather than a fundamental lack of trust or explainability—I would pivot to the **Usage Quality Sprint** to prioritize rapid technical iteration over qualitative workflow analysis.

================  OUT-10  ================

---
anonymous_label: OUT-10
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 2abf9296111007f0510185db8afe8733f61879321d53dad6a7c74d6bc9ee4b2a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-10

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should recommend that the CEO prioritize the Commercial Cleanroom over scaling SignalPath or running internal usage/file reviews.

The current "strong quarter" is heavily contaminated by what **BK-0048-card-001** describes as the **halo effect**: because expansion bookings rose and renewals closed early, leadership is now attributing "focus" and "commercial discipline" to the product team. However, your evidence suggests these traits are not independent causes of success but reflections of a performance signal driven by temporary bundle pricing and sales-led roadmap pitches.

The Commercial Cleanroom is the only proposed package that isolates the performance signal from the product's actual value. By removing the bundle-price incentive and the roadmap pitch, you test whether buyers are purchasing SignalPath because it solves a problem or because of a financial incentive. This is the only way to determine if your "strong quarter" is based on **validated learning** (empirical evidence of customer behavior) or mere execution targets like booking growth, which **BK-0007-card-001** warns can be misleading under uncertainty.

### The Strongest Reason Against It
The strongest reason against this recommendation is the immediate risk to short-term revenue. By stopping bundle-price offers and withholding the roadmap pitch for a matched set of accounts, you are intentionally removing levers that have historically accelerated renewals and expansion. If the board is primarily focused on hitting next year's growth targets rather than validating the product-market fit of SignalPath, this approach will be viewed as sabotaging the sales pipeline for the sake of academic rigor.

### Evidence That Would Change My Mind
I would change this recommendation if you could provide a **Diagnosis** (per the strategy kernel in **BK-0001-card-001**) that proves the "strong quarter" was driven by a specific, identified customer challenge that SignalPath solves, rather than the pricing bundles. Specifically, if you had empirical data showing that customers who *did not* receive the bundle price still expanded their accounts specifically to get SignalPath, the Commercial Cleanroom would be redundant. In that case, the "performance signal" would already be decoupled from the financial incentive, and you could safely move to scaling or narrowing the workflow focus.

================  OUT-11  ================

---
anonymous_label: OUT-11
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 37699356c5c7d102dc3b80b27e299b5202def00c6e82c02bef7543f52960ce90
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-11

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should displace the "scale SignalPath broadly" commitment. Scaling now would be an act of faith based on contaminated data; the Commercial Cleanroom is the only proposed package that isolates whether SignalPath is actually driving commercial value or if you are simply seeing a temporary spike caused by bundle pricing and sales-led optimism.

**Reasoning:**
Your current "strong quarter" is a textbook example of the **halo effect** (BK-0048-card-001). Because the overall performance signal is positive (expansion bookings up 16%), your leadership is retrospectively attributing this success to the product team's "focus" and "discipline." However, the evidence suggests these trait assessments are not independent:
1. **Financial Noise:** Expansion dollars are tied to temporary bundle pricing, not necessarily product value.
2. **Narrative Noise:** Enthusiastic customer comments were collected *after* sales pitched SignalPath as the roadmap centerpiece, meaning buyers are reacting to a promise, not the current utility.
3. **Usage Noise:** The 39% usage increase is driven by managers rerunning samples (internal enablement) rather than front-line adjusters solving claims.

The "Usage Quality Sprint" and "Claim File Review" measure *how* the tool is used, but they do not solve the primary strategic risk: that the current commercial success is an illusion. The Commercial Cleanroom tests the "validated learning" (BK-0007-card-001) required to prove that SignalPath is a driver of revenue rather than a passenger to a pricing promotion.

### The Strongest Reason Against
The Commercial Cleanroom creates immediate friction with the Sales organization and risks a short-term dip in expansion bookings. By withholding bundle pricing and roadmap pitches from a matched set of accounts, you are intentionally removing the "accelerants" that produced this quarter's success. In a high-pressure environment where the board is locking budgets in twelve days, sacrificing guaranteed (albeit artificial) short-term wins for empirical truth can be politically perilous.

### Evidence That Would Change My Mind
I would change this recommendation if the **Claim File Review** provided immediate, empirical evidence that front-line adjusters in *non-regulated* segments were accepting and acting on SignalPath suggestions at a high rate without manager intervention. If the "coherent action" (BK-0001-card-001) of the adjusters already aligns with the product's intended value proposition, the risk shifts from "is this a fluke?" to "how do we fix the enablement gaps?", making the Claim File Review the higher-priority diagnostic.

================  OUT-12  ================

---
anonymous_label: OUT-12
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 47a8dc283b82bbf4a9165114957b6e98302d7bce3cca4a26a797c2f508381125
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-12

I recommend you commit to the **Claim File Review**.

### The Recommendation: Claim File Review
You are currently operating in a "false positive" environment. Your financial wins are driven by pricing incentives (the bundle), your usage spikes are driven by managers (not the end-users), and your support metrics are masked by a shift in ticketing channels.

The Claim File Review is the only option that bypasses these proxies to uncover the **ground truth of value**. By auditing actual claim files, you determine if SignalPath is actually solving the core problem (complex claims workflow) or if it is simply a "theatre of productivity" that managers like but adjusters find useless or unexplainable. This is the only way to determine if you have a scalable product or a well-marketed feature that will collapse once the bundle pricing expires.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and provides a small sample size compared to the Usage Quality Sprint. While you are auditing files, the board may perceive a lack of "velocity." By choosing this over the Commercial Cleanroom, you risk entering next year with a pricing strategy that is still inflated by artificial incentives, potentially leading to a "churn cliff" when the bundle offers end and the actual value proposition fails to hold.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "unexplainable" nature of the recommendations in health-liability is a minor UI/documentation issue rather than a fundamental algorithmic failure.

If the Claim File Review reveals that adjusters *do* find the suggestions accurate but simply lack the "paper trail" to justify them to reviewers, the product risk is solved. At that point, your primary risk shifts from **Product-Market Fit** (Does it work?) to **Commercial Viability** (Will they pay full price?). If the utility is proven, you must immediately switch to the Cleanroom to validate that the growth is organic and not a byproduct of sales engineering.

================  OUT-13  ================

---
anonymous_label: OUT-13
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 4958df2b153d75fa3cf4f3c536d1a7a41af840223c53dbe2afc4902af76c0d25
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-13

**Recommendation:** Run the Claim File Review.

**Reasoning:** The current growth indicators are heavily contaminated. Expansion revenue is tied to temporary pricing incentives rather than perceived value, and positive customer sentiment was elicited by sales teams promising future roadmap items. Usage spikes are driven by managers auditing old files rather than adjusters managing live claims.

The Claim File Review is the only intervention that accesses non-independent evidence by examining the actual work product (the claim file) rather than self-reported sentiment or superficial activity logs. It reveals whether the software is actually solving the problem or if adjusters are simply performing "compliance theater" for their managers. While the Usage Quality Sprint tracks *if* they return, and the Commercial Cleanroom tracks *if* they pay, only the File Review explains *why* they abandon the tool—specifically addressing the "impossible to explain" failure point in regulated segments.

**Strongest Reason Against:** This is a manual, slow process that provides a small sample size. It cannot prove statistical causality for the 16% revenue lift and may be completed too late to influence the budget if the board requires quantitative certainty rather than qualitative insight.

**Evidence that would change this recommendation:** If you discover that the "impossible to explain" abandonment is limited to a tiny fraction of users and that the 39% usage increase is driven primarily by front-line adjusters in non-regulated segments who are successfully closing claims faster. In that case, the bottleneck is a niche regulatory issue rather than a core product-market fit failure, making the Commercial Cleanroom the priority to validate pricing power.

================  OUT-14  ================

---
anonymous_label: OUT-14
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 4d99c8290b000681ebe6ea3c76e9d79da05e12869b4b13a29685da051dcd9416
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-14

**Recommendation: Run the Claim File Review.**

This intervention provides independent evidence by bypassing the contaminated signals of bundle-pricing and sales-driven enthusiasm. While usage numbers are up, they are skewed by managers running samples rather than adjusters performing live work. The file review reveals the actual utility of the output—whether it is accepted or rewritten—which exposes if the tool is solving a problem or simply being "used" to satisfy management oversight.

**Strongest Reason Against:**
This approach is slow and manual compared to the Usage Quality Sprint. It will not provide a real-time dashboard of return rates or a statistically significant sample size across all segments before the budget deadline. It risks identifying specific failures without proving whether those failures are caused by poor product logic or merely a lack of training.

**Evidence that would change this recommendation:**
If the Commercial Cleanroom were modified to include a "silent" period where current users are asked to perform their tasks without the tool for one week, and the resulting drop in claim-processing speed was negligible, I would switch to the Cleanroom. Such a result would prove that the product is not providing core value, rendering the detailed file review an academic exercise in a failing feature.

================  OUT-15  ================

---
anonymous_label: OUT-15
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 544d01cb3a14a7eb041fc1619a55206924d52eda5e87a2f6ef334b6b15af7cf0
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-15

**Recommendation:** Run the **Claim File Review**.

**Why:**
Your current success is an "entangled" signal. The financial growth is likely a result of pricing bundles and sales narrative (the "Halo Effect") rather than product value. The usage data is a vanity metric: managers are using the tool for auditing/training, while the actual end-users (adjusters) are abandoning it.

The Claim File Review is the only option that addresses the core risk: a lack of "Jobs-to-be-Done" fit. By analyzing whether suggestions were accepted, overridden, or "impossible to explain," you move past aggregated usage percentages and discover *why* the product is failing in regulated segments and why adjusters revert to manual notes. This provides the ground-truth evidence needed to decide if SignalPath requires a pivot in logic, better explainability features, or a narrower market focus before you commit next year's budget to scaling a leaky bucket.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation tests. Unlike the Usage Quality Sprint (which relies on automated dashboards) or the Commercial Cleanroom (which relies on sales outcomes), a file review requires manual qualitative analysis. By choosing this, you sacrifice the ability to immediately quantify the financial impact of the bundle-pricing distortion (the Cleanroom) and the ability to track real-time behavioral shifts (the Sprint).

**Observable evidence that would change my mind:**
If the "regional carriers" who intend to remove SignalPath provide specific, documented feedback stating that their objection is purely based on the *price* of the bundle rather than the *utility* of the feature. If the friction is purely commercial and not functional, the Commercial Cleanroom would become the priority to determine the true price elasticity of the product.

================  OUT-16  ================

---
anonymous_label: OUT-16
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 55d63de2aab5c19edc3cab9922b22e8c19cbec6a5f725d321e0ccc1d288b8620
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-16

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should displace the "scale SignalPath broadly" commitment. By choosing the Cleanroom, you sacrifice immediate potential revenue growth from bundle-pricing and the momentum of a "roadmap pitch" in exchange for an honest assessment of whether SignalPath has actual market value or is merely a byproduct of pricing incentives and sales narratives.

**Reasoning:**
Your current situation exhibits a classic **halo effect** (BK-0048-card-001). Because expansion bookings rose and renewals closed early (the overall performance signal), your leadership has retrospectively attributed these results to the product team being "focused" and "aligned around the right buyer." However, the underlying evidence suggests this is a distortion:
1. **Financials:** Expansion dollars are tied to temporary bundle pricing, not necessarily product value.
2. **Customer Sentiment:** Enthusiastic comments were collected *after* sales teams pitched SignalPath as the future centerpiece, potentially priming the buyers.
3. **Usage:** The 39% rise is driven by managers rerunning samples (internal enablement) rather than front-line adjusters utilizing the tool for its intended purpose.

Without the Cleanroom, you are scaling a product based on "halo-tinted" data. The Cleanroom is the only proposal that isolates the performance signal from the product's actual value by removing the pricing and pitching variables.

### The Strongest Reason Against This Recommendation
The Commercial Cleanroom creates a significant short-term risk to the "surprising strong quarter" momentum. By stopping bundle-price offers and withholding the roadmap pitch, you may see an immediate dip in expansion bookings or a slowing of renewal cycles. In a board-driven environment with a 12-day budget window, the CEO may view this as "sabotaging" a winning streak to satisfy an academic need for data purity.

### Observable Evidence That Would Change My Mind
I would change this recommendation if you could provide **validated learning** (BK-0007-card-001) that the current usage is not "waste." Specifically, if you could show a core metric—such as *adjuster return rates* or *reduction in claim cycle time*—that is increasing independently of manager-led enablement meetings and bundle pricing. If the front-line adjusters in non-regulated segments are adopting the tool without manager oversight, it would suggest a genuine product-market fit that justifies scaling despite the noise in the financial data.

================  OUT-17  ================

---
anonymous_label: OUT-17
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 56a3f8625cfc50a973d4981bc34fac7447ff84ef4b9c04191af5b53960ed1b8b
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-17

**Recommendation:** Run the **Claim File Review**.

**Why:**
Your current success is an illusion created by "entangled" data. The expansion bookings are driven by temporary pricing bundles (financial incentive) and roadmap promises (future hope), not proven product value. The usage spike is driven by managers (supervisors) rather than adjusters (users), and the "drop in tickets" is likely a result of users shifting their complaints to training channels rather than a sign of product quality.

You are facing a "false positive" signal. The Usage Quality Sprint only measures *if* they use it, and the Commercial Cleanroom only measures *if* they will pay for it. Neither tells you *why* the front-line adjusters are abandoning the tool or why health-liability users cannot justify the output to reviewers. To scale a product that is being ignored by its primary user or failing regulatory scrutiny is to build on a foundation of sand. The Claim File Review is the only option that provides ground-truth evidence of whether the product actually solves the problem it claims to solve.

**The strongest reason against this:**
It is slow and manually intensive. Unlike the Usage Quality Sprint (which relies on automated dashboards) or the Commercial Cleanroom (which relies on sales outcomes), a file review requires human labor to audit specific claims. With the board budget lock only twelve days away, this provides a "lagging" qualitative insight rather than an immediate quantitative metric that executives typically prefer for budget justifications.

**Observable evidence that would change my mind:**
If the "regional carriers" who are already planning to remove SignalPath from their contracts provide explicit, written feedback stating that the product is technically sound but the *price* is too high or the *bundling* was misleading. If the failure is purely commercial/packaging rather than functional/workflow-based, the Commercial Cleanroom would become the priority to fix the pricing model before scaling.

================  OUT-18  ================

---
anonymous_label: OUT-18
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 5981d94ab662a8b8f7d8e33cad42e46a0a9ab1f11139862517deb739dbaa38a2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-18

I recommend that you commit to the **Claim File Review**.

### Reasoning and Trade-offs
Your current situation is a classic "false positive" signal. You have strong lagging indicators (bookings, renewals) but alarming leading indicators (adjuster abandonment, "ghost" usage by managers, and upcoming churn in regional carriers).

The expansion bookings are contaminated by a temporary pricing bundle—meaning the customers bought a *deal*, not necessarily a *solution*. The usage spike is misleading; managers using the tool for "samples" in enablement meetings is a training activity, not a workflow integration.

You are facing a critical "Value Gap": the tool provides a suggestion, but the user cannot justify that suggestion to their internal reviewer (especially in health-liability). If a B2B tool creates more work for the user (explaining the AI) than it saves them, they will eventually churn regardless of the initial sales pitch.

**Why this over the others?**
*   **Against Scaling Broadly:** This is reckless. You have evidence of abandonment and impending churn. Scaling a leaky bucket only accelerates the crash.
*   **Against the Usage Quality Sprint:** This measures *that* people are leaving, but not *why*. You already know they fall back to manual notes. More dashboards won't tell you how to fix the logic or the explainability problem.
*   **Against the Commercial Cleanroom:** This is a sales experiment. While it would prove that SignalPath isn't driving the renewals, it doesn't provide a path to fixing the product. You don't need to prove the sales pitch is misleading; you already have enough evidence of that.
*   **Against Narrowing to Health-Liability:** This is premature. You don't know if the "explainability" issue is a universal flaw in SignalPath or a specific regulatory hurdle for health-liability.

The **Claim File Review** is the only option that treats the product as a workflow tool rather than a sales asset. By seeing exactly where suggestions are overridden or rewritten, you move from "usage percentages" to "utility truths." You will discover if the tool is actually wrong, or if it's right but "un-explainable."

### The strongest reason against this recommendation
The Claim File Review is slow, manual, and "un-scalable." It provides a small sample size compared to the Usage Quality Sprint. By choosing this, you sacrifice the ability to provide the board with a high-confidence, company-wide quantitative metric on retention. You are trading "big data" (which is currently lying to you) for "thick data" (which is harder to present in a board deck).

### Observable evidence that would change my mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "regional carrier churn" was not caused by product failure, but by a specific change in their procurement policy or a competitor's aggressive pricing. If the product is actually working (as evidenced by the adjusters) but the *buyers* are simply refusing to pay for it, you have a pricing/packaging problem, not a product-market fit problem. In that case, the Cleanroom is the only way to isolate the commercial value.

================  OUT-19  ================

---
anonymous_label: OUT-19
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 5fbfc3a8c64cd4d452f624ea27eb041f8659104e906282b854d4a6a61b5069fd
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-19

I recommend you commit to the **Claim File Review**.

### The Rationale
Your current growth is an "illusion of success" driven by sales incentives (bundle pricing) and managerial vanity (ops managers auditing closed files), rather than adjuster utility. You have a critical **efficacy gap**: front-line adjusters abandon the tool after two days, and those in regulated segments cannot justify its output to auditors.

Scaling now would be premature; the Usage Quality Sprint only tracks *that* people are using it (which is already skewed by managers), and the Commercial Cleanroom only tests *willingness to pay* (which is a lagging indicator of value). The Claim File Review is the only option that solves for **product-market fit at the user level**. By seeing exactly where suggestions are overridden or "impossible to explain," you move from tracking activity to understanding utility. You cannot build a sustainable roadmap until you know if SignalPath is actually solving the claim or just creating more work for the adjuster to "fix" the software's suggestion.

### The Strongest Reason Against It
This is a slow, qualitative process that provides no immediate "win" for the sales team or the board. While you are manually reviewing files, your competitors may move faster to capture market share, and your sales team will lose the "SignalPath momentum" they are currently using to close renewals. You are trading short-term commercial velocity for long-term product stability.

### The Evidence That Would Change My Mind
I would pivot to **Scaling SignalPath Broadly** if you could produce data showing that the "manual notes" adjusters are falling back on are actually *derived from* SignalPath’s initial drafts. If the software is acting as a "starter motor" that accelerates the first 20% of the work—even if it isn't used for the final 80%—the value proposition shifts from "automated planning" to "accelerated drafting." In that case, the abandonment isn't a failure of utility, but a natural workflow transition, making aggressive scaling the correct move.

================  OUT-20  ================

---
anonymous_label: OUT-20
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 600f0314e8f4b48dd5fd35f50ce92cd018cdbfd6408a6b3190c9a13d21ef0386
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-20

I recommend that you commit to the **Claim File Review**.

### Reasoning: The "False Positive" Trap
Your company is currently experiencing a classic "false positive" signal. Your financial metrics (expansion bookings) and sentiment metrics (enthusiastic comments) are being driven by **incentives**, not **utility**.

The expansion is tied to a temporary bundle price; the enthusiasm is tied to a roadmap promise. These are "buying the future" behaviors, not "using the product" behaviors. Meanwhile, your usage data is misleading: manager-led sample runs are "vanity usage" that doesn't translate to adjuster productivity.

The most alarming signal is the "explainability gap" in health-liability and the rapid drop-off in adjuster adoption. If adjusters cannot justify a SignalPath action to a reviewer, the product is not a workflow tool—it is a liability. If you scale now, you are scaling a product that users abandon once the "newness" wears off or the manager stops watching.

**Why not the other options?**
*   **Scale SignalPath:** This is high-risk. You have early evidence of churn (regional carriers) and a lack of "stickiness" among front-line users. Scaling now would likely lead to a churn crisis in 6–9 months.
*   **Usage Quality Sprint:** This measures *that* people are leaving, but not *why*. You already know they fall back to manual notes; more dashboards won't tell you if the recommendations are wrong or simply unexplainable.
*   **Commercial Cleanroom:** This tests sales elasticity, not product-market fit. You don't need to know if you can sell it without a discount; you need to know if the product actually solves the problem.
*   **Narrow to Health-Liability:** This is premature. You have a specific failure point there (explainability), but you don't yet know if the core logic of SignalPath is fundamentally flawed across all segments.

### The Recommendation: Claim File Review
The Claim File Review is the only option that provides **ground-truth evidence**. By auditing actual files, you move from *proxy metrics* (clicks/bookings) to *outcome metrics* (accepted vs. overridden). This will tell you if the product is actually providing value or if it's just a "suggestion engine" that adjusters ignore in favor of their own intuition.

### The Strongest Reason Against It
**Velocity and Board Optics.** A Claim File Review is slow, manual, and "un-sexy" compared to a growth narrative. The CEO and Board are currently riding a high from a strong quarter. Recommending a manual audit instead of "scaling the winner" may be perceived as a lack of confidence or an attempt to slow down momentum. You are choosing a "defensive" diagnostic over an "offensive" growth strategy at a time when the company feels it has found its stride.

### Evidence That Would Change My Mind
I would pivot to **Scaling SignalPath** if the "Regional Carrier" churn was revealed to be purely a budget/procurement issue rather than a utility issue. Specifically, if those carriers stated: *"We love the tool and it's working, but we simply don't have the budget line-item for this specific module next year,"* rather than *"Our adjusters aren't using it."* If the failure is financial rather than functional, the risk of scaling is significantly lower.

================  OUT-21  ================

---
anonymous_label: OUT-21
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 6a6e66a2ad964d6eceed257fd769e663f2b3a0262b5213caeb7883bd3f58335d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-21

I recommend the **Claim File Review**.

**Why:**
The company is currently experiencing "false positives" across every primary success metric. The rise in bookings is tied to temporary pricing bundles; the usage spike is driven by managers auditing closed files rather than adjusters working live claims; and the drop in support tickets is a result of re-categorization (enablement requests) rather than improved product quality.

The core risk is a "value gap": customers are buying the *promise* of SignalPath (the roadmap pitch), but front-line adjusters are abandoning it in practice because they cannot justify the outputs to reviewers. The Claim File Review is the only proposed option that bypasses lagging indicators (like churn reporting) and vanity metrics (like total usage) to diagnose exactly why the product is being overridden or abandoned. This provides the ground-truth evidence needed to decide if SignalPath requires a pivot in logic, a change in UI for "explainability," or if the product-market fit is an illusion.

**The strongest reason against it:**
It is a manual, qualitative process that provides a small sample size. Unlike the Usage Quality Sprint or Commercial Cleanroom, it will not provide statistically significant "hard" data on revenue or broad user behavior, which may feel insufficient to a board looking for quantitative certainty before locking a budget.

**Observable evidence that would change my mind:**
If the "regional carrier" churn (the accounts already planning to remove SignalPath) was revealed to be driven exclusively by pricing/budget cuts rather than product utility, I would shift the recommendation to the **Commercial Cleanroom**. This would indicate that the product value is actually high, and the primary risk is a flawed pricing strategy rather than a failure of the workflow software.

================  OUT-22  ================

---
anonymous_label: OUT-22
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 6fa34c4b67f1a750f9e029d60cf67ada7e962227946534a55d33c93964cd3b14
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-22

I recommend that you commit to the **Claim File Review**.

### Reasoning and Tradeoffs

You are currently facing a "false positive" crisis. Your lagging indicators (bookings, renewals) look strong, but your leading indicators (adjuster behavior, health-liability abandonment) are flashing red.

The current growth is likely driven by **sales momentum and pricing incentives**, not **product value**. The "bundle price" created an artificial incentive to renew, and the roadmap pitch created a psychological commitment from buyers that hasn't yet been tested by actual utility. The fact that adjusters revert to manual notes unless monitored suggests SignalPath is currently a "compliance tool" (used because the boss is watching) rather than a "productivity tool" (used because it makes the job easier).

Here is why the other options are insufficient:
*   **Scale Broadly:** This is high-risk. If the product lacks core utility for adjusters, you are scaling a "leaky bucket." You will see a massive spike in churn 12 months from now when the bundle prices expire and the "roadmap promises" are due.
*   **Usage Quality Sprint:** This measures *what* is happening (retention/return rates), but not *why*. You already know the "what": adjusters stop using it after two days. More dashboards won't tell you if the suggestions are wrong or simply unexplainable to regulators.
*   **Commercial Cleanroom:** This tests the *sales pitch*, not the *product*. While it would prove that the bundle pricing is driving growth, it doesn't help you fix the product to ensure those customers actually stay.
*   **Narrow to Health-Liability:** This is a premature pivot. You have evidence of failure in this segment, but you don't yet have a diagnostic of why the product is failing across *all* segments.

The **Claim File Review** is the only option that provides a "ground truth" diagnostic. By looking at whether suggestions were accepted, overridden, or rewritten, you move from *proxy metrics* (usage clicks) to *value metrics* (correctness and utility). This allows you to determine if SignalPath is a "feature" that needs tuning or a "fundamental flaw" in logic.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitatively driven. It does not provide the "hard" financial data that a Board typically wants to see when locking a budget. By choosing this, you are sacrificing the ability to definitively prove—via the Commercial Cleanroom—exactly how much of your recent revenue growth was "fake" (incentive-driven) versus "real" (value-driven). You are betting on **product-market fit** over **revenue attribution**.

### Evidence That Would Change My Mind
I would change this recommendation to the **Commercial Cleanroom** if you discovered that your current cash runway is critically low (e.g., less than 12 months). If the company is in a "survival" mode where you must maximize short-term bookings to avoid a funding crisis, the product's long-term utility is secondary to knowing exactly which pricing levers drive immediate cash. If the goal is survival, you optimize for the sale; if the goal is a sustainable business, you optimize for the Claim File.

================  OUT-23  ================

---
anonymous_label: OUT-23
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 70533327d4e8a7fb32afa33ed7b1e2b2334cb2a3f708f446f99e68449d344c67
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-23

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should recommend this package because your current evidence of success is heavily "halo-tinted" (BK-0048-card-001). The executive team's perception of the product team as "focused" and "commercially disciplined" is a reflection of the strong quarter's results, not independent evidence of those traits.

The financial data is currently contaminated by a "bundle price" incentive that creates an artificial spike in expansion bookings, and the customer sentiment is biased by a roadmap pitch. To determine if SignalPath has actual market value or if you are simply seeing the effect of pricing incentives and sales narratives, you must isolate the performance signal. The Commercial Cleanroom is the only proposed test that removes these confounding variables to see if the product's value proposition stands on its own.

### The Strongest Reason Against It
The strongest reason against this recommendation is that it ignores critical "validated learning" failures regarding the product's actual utility (BK-0007-card-001). While the Cleanroom tests *willingness to pay*, it does not address why front-line adjusters abandon the tool after two days or why health-liability users cannot explain the recommendations to reviewers. By focusing solely on the commercial signal, you risk scaling a product that is fundamentally broken in its workflow (waste), even if the sales team can successfully sell it via bundles.

### Evidence That Would Change My Mind
I would change this recommendation to the **Claim File Review** if you could provide evidence that the "bundle price" accounts are renewing based on actual tool usage rather than the discount. Specifically, if data showed that the customers who paid the expansion premium are also the ones with high "return rates" (adjusters using the tool consistently beyond the first two days), it would prove that the commercial signal is already valid. In that case, the primary risk shifts from "are we selling a mirage?" to "is the product actually working?", making the Claim File Review the highest-leverage path to validated learning.

================  OUT-24  ================

---
anonymous_label: OUT-24
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 815769779a12420c1ff80f8d0ba6bfee6c9a6d26e45f6e0d10874d979cae4d9c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-24

I recommend the **Claim File Review**.

**Why:**
The current success is "entangled" and likely illusory. The financial wins are skewed by temporary pricing bundles, the usage spike is driven by managers (not front-line adjusters), and the "reduction" in support tickets is actually a shift in reporting channels. Most critically, you have a qualitative failure in the health-liability segment where users cannot explain the product's logic to reviewers.

The Usage Quality Sprint tracks *behavior* (which is already skewed by manager activity), and the Commercial Cleanroom tests *pricing/sales psychology*. Neither addresses whether the product actually solves the core problem. The Claim File Review is the only option that provides "ground truth" by auditing the output (accepted vs. overridden) and identifies why adjusters are abandoning the tool. Before scaling or narrowing the roadmap, you must determine if SignalPath is providing genuine utility or simply "noise" that managers enjoy auditing.

**The strongest reason against it:**
It is a slow, manual process that provides a small sample size compared to the automated, high-volume data of the Usage Quality Sprint. In a twelve-day window before budget locks, this qualitative approach may feel too anecdotal to satisfy a board looking for "hard" metrics.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets—once properly re-aggregated from the training channel—show a statistically significant and consistent decline in error rates across all segments (not just health-liability), it would suggest the product is functionally sound and the issue is purely one of enablement. In that case, I would pivot to the **Usage Quality Sprint** to optimize adoption.

================  OUT-25  ================

---
anonymous_label: OUT-25
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 905d8d82c450af871f20023155a7dadf3600326acbc1ea4a0c020f80581134cc
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-25

**Recommendation:** Run the Claim File Review.

**Why:** Your current "strong quarter" is an illusion created by lagging indicators (renewals) and skewed incentives (bundle pricing). You have a critical "truth gap": the executive team believes you are aligned with the buyer, but the behavioral data suggests a failure in the core value proposition.

The Usage Quality Sprint tracks *if* people use it, but not *why* (e.g., managers using it for audits rather than adjusters using it for work). The Commercial Cleanroom tests *willingness to pay*, but you cannot fix the pricing of a product that users are abandoning due to lack of explainability. The Claim File Review is the only option that addresses the "hidden churn" and the specific failure mode in regulated segments. By inspecting the actual output (accepted vs. overridden), you determine if SignalPath is providing genuine utility or if it is merely a "theatre of productivity" that satisfies managers while hindering adjusters.

**The strongest reason against it:** It is the slowest and most labor-intensive of the validation tests. Unlike a dashboard (Usage Quality Sprint) or a sales experiment (Commercial Cleanroom), it requires manual qualitative analysis of files, which may feel too slow given the twelve-day budget window.

**Observable evidence that would change my mind:** If the "regional carrier" churn (the two accounts planning to remove SignalPath) is revealed to be based solely on a specific procurement budget cut rather than product dissatisfaction. If the churn is purely financial and not functional, the Commercial Cleanroom becomes the priority to protect margins.

================  OUT-26  ================

---
anonymous_label: OUT-26
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 91e273c1a4c9154516a6bf9525799057997e47ef46a75753d43fe2a31113b702
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-26

### Recommendation: Run the Claim File Review

You should recommend the **Claim File Review**.

#### Reasoning
Your current data is "noisy" and likely misleading. You are seeing a classic case of **lagging indicators (bookings/renewals) masking leading failures (usage patterns).**

1.  **The Revenue Mirage:** The 16% expansion rise is contaminated by a "bundle price" incentive. You aren't measuring the value of SignalPath; you are measuring the effectiveness of a discount strategy.
2.  **The Usage Mirage:** A 39% increase in usage is a vanity metric if the activity is primarily managers auditing closed files. This is "administrative usage," not "operational value."
3.  **The Adoption Gap:** The behavior of front-line adjusters (high initial use, then abandonment) suggests the tool provides a "novelty spike" but fails to integrate into the daily habit of claims handling.
4.  **The Compliance Wall:** In health-liability, the "explainability" gap is a fatal flaw. If an adjuster cannot defend a recommendation to a reviewer, the software becomes a liability rather than an asset.

The **Usage Quality Sprint** is too superficial; it tracks *if* they return, not *why* the output was rejected. The **Commercial Cleanroom** is too risky; it tests sales psychology, not product utility, and could jeopardize the momentum the board currently sees.

The **Claim File Review** is the only option that addresses the "Ground Truth." By auditing actual files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. rewritten suggestions). This will tell you if SignalPath is actually solving the problem or if it is simply a "suggestion engine" that adjusters ignore once the novelty wears off.

#### The Tradeoffs
By choosing this, you are displacing **Scaling SignalPath Broadly**.

**What you give up:** You sacrifice the "momentum play." If SignalPath actually *is* a hit and you are just being overly cautious, you lose the first-mover advantage to capture more market share while the executive team is bullish. You risk a "cooling off" period where Sales feels Product is slowing down the commercial engine.

#### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a "snapshot" rather than a real-time dashboard. There is a risk that the sample size will be too small to be statistically significant, leading the board to view the results as anecdotal while Sales continues to point at the (discount-driven) expansion bookings as "proof" of success.

#### Evidence That Would Change My Mind
I would pivot to **Narrowing the plan around regulated health-liability workflows** if the Claim File Review reveals that SignalPath’s core logic is fundamentally sound, but the "explainability" gap is the *only* reason for abandonment.

If the review shows that adjusters in non-regulated segments are also overriding suggestions (not just health-liability), the product has a general utility problem. But if non-regulated users are accepting suggestions at high rates and only health-liability users are struggling, the product is a success—it just requires a specialized "compliance/audit" layer to unlock its most lucrative and difficult segment.

================  OUT-27  ================

---
anonymous_label: OUT-27
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 9707a46c87e197fb50a01c665e115b763bee6570cc84b8e4b0d6f56a8659e1d6
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-27

**Recommendation:** Run the **Claim File Review**.

**Why:** Your current success is "entangled." The financial growth is likely an artifact of pricing bundles rather than product value, and the usage spikes are driven by managers (for reporting) rather than adjusters (for workflow). You have a critical "black box" problem: in regulated segments, the product is being abandoned because it lacks explainability. The Claim File Review is the only proposed action that provides a ground-truth diagnostic of *why* the software is being overridden or ignored. It moves beyond surface-level telemetry (Usage Quality Sprint) and sales psychology (Commercial Cleanroom) to determine if SignalPath is actually solving the core problem or simply providing a "draft" that adjusters find too risky or cumbersome to use.

**Strongest Reason Against:** This is a qualitative, manual process that is slower and less scalable than the Usage Quality Sprint. By choosing this, you sacrifice the ability to track real-time behavioral trends across the entire user base and risk missing a broader "leaky bucket" trend that event tracking would have flagged instantly.

**Observable Evidence to Change My Mind:** If the "Commercial Cleanroom" data were available now and showed that expansion bookings remained high even without bundle pricing or roadmap pitches, I would shift my recommendation. That evidence would prove the perceived value is real and decoupled from sales tactics, making "Scale SignalPath Broadly" the correct move.

================  OUT-28  ================

---
anonymous_label: OUT-28
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 9a7f940bcbc7da9fbc18abf4108a1fe94fef78b724d05ad59d7255681aafec58
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-28

I recommend that you commit to the **Claim File Review**.

**Why:**
Your current success is "entangled"—the positive financial metrics are likely skewed by temporary pricing bundles and the usage metrics are inflated by managers running samples rather than adjusters managing live claims. You have a critical "black box" problem: you know that front-line adjusters abandon the tool and health-liability users cannot explain its logic, but you don't know *why* the recommendations are being overridden or ignored. The Claim File Review is the only proposal that provides qualitative, ground-truth evidence of product-market fit. It bypasses the "enthusiastic" but biased sales feedback and reveals whether SignalPath actually solves a workflow problem or is simply a novelty that managers like but practitioners find useless.

**The strongest reason against it:**
This approach is slow and manual compared to the Usage Quality Sprint. It provides a snapshot of specific files rather than a continuous stream of behavioral data, meaning you risk making a strategic decision based on a small sample size while the board's budget window closes.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel spike significantly or if the regional carriers who are removing SignalPath provide specific, documented feedback that the tool's output is fundamentally inaccurate (rather than just "hard to explain"), I would pivot to the **Usage Quality Sprint**. This would indicate that the problem is a technical failure of the recommendation engine (requiring rapid iteration) rather than a workflow/enablement failure (requiring the deep-dive review).

================  OUT-29  ================

---
anonymous_label: OUT-29
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 9c5454476fea96345111cdd143869c8ab1ab4bcad8b42e8827ee71bcff91b14f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-29

**Recommendation: Run the Commercial Cleanroom.**

The current growth is heavily contaminated by financial incentives (bundle pricing) and sales narratives (roadmap promises) rather than product value. The expansion bookings are a trailing indicator of a pricing promotion, not a leading indicator of feature demand. Because the sales cycles shortened specifically after buyers were told SignalPath would be the "centerpiece" of the future, you are likely measuring the perceived value of a promise rather than the utility of the current tool. The Commercial Cleanroom is the only intervention that isolates whether a buyer will pay for the product as it exists today, without the noise of discounts or future expectations.

**Strongest Reason Against:**
This approach risks immediate revenue. By withholding bundle pricing and the roadmap pitch from a segment of renewals, you may intentionally slow down expansion bookings or trigger objections that would have otherwise been suppressed by the promotion. This could create a short-term dip in performance metrics just as the board is locking the budget.

**Evidence That Would Change This Recommendation:**
If you discover that the regional carriers planning to remove SignalPath are outliers with unique technical constraints, and instead find that front-line adjusters in other segments are overriding the tool not because of a lack of trust, but because the tool is missing one specific, easily buildable data field. In that case, the problem would be a minor gap in utility rather than a fundamental lack of market-product fit, making the Claim File Review more valuable.

================  OUT-30  ================

---
anonymous_label: OUT-30
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: a1357fd92108c9a788bc2519f2155c44134ecadcb58bff618267c5033bbf51a4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-30

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should displace the "scale SignalPath broadly" commitment. Scaling now would be an act of faith based on contaminated data; the Cleanroom is the only proposed package that isolates whether SignalPath is actually driving growth or if you are merely witnessing a temporary pricing artifact.

**Reasoning:**
Your current "strong quarter" is highly susceptible to the **halo effect** (BK-0048-card-001). Because overall performance is up (expansion bookings rose 16%), your executives are attributing this success to the product team’s "focus" and "commercial discipline." However, the evidence suggests these trait assessments are not independent: expansion dollars are tied to temporary bundle pricing, and positive customer comments were elicited after sales pitched SignalPath as a future centerpiece. You are seeing the "performance signal" (revenue) coloring the perception of the "attribute" (product strategy).

Furthermore, your current measures of progress are "vanity numbers" rather than **validated learning** (BK-0007-card-001). Usage rose 39%, but the activity is driven by managers (not front-line users) and temporary rollout spikes. Scaling broadly based on these metrics would be "waste," as you have not yet proven that the product provides value that customers will pay for without a discount or a roadmap promise. The Commercial Cleanroom is the only method that tests the actual value proposition by removing the pricing and pitching noise.

### The Strongest Reason Against It
The Cleanroom carries significant short-term political and financial risk. By stopping bundle pricing and withholding the roadmap pitch, you are intentionally slowing down the sales velocity that the executive team currently credits as a sign of "alignment." If expansion bookings dip during this test, it may be interpreted by the board not as a successful experiment in validated learning, but as a loss of commercial momentum, potentially jeopardizing the budget for other initiatives.

### Observable Evidence That Would Change My Mind
I would change this recommendation to the **Claim File Review** if you could produce evidence that the "abandonment" in the regulated health-liability segment is a minor edge case rather than a systemic failure of the product's core logic. If current data showed that front-line adjusters in *non-regulated* segments were maintaining high return rates without manager oversight, the primary risk would shift from "commercial validity" (the Cleanroom's focus) to "product utility/explainability" (the Review's focus).

================  OUT-31  ================

---
anonymous_label: OUT-31
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: a173d906430f0ad23aab641dd558854bb15c49669efea9be36729c866ce20944
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-31

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is an "entangled" illusion. The financial gains are driven by pricing incentives (bundle discounts) and sales narratives (roadmap promises), not necessarily product value. The usage data is misleading: "high-frequency activity" is coming from managers performing audits, not adjusters performing work. Most critically, the "abandonment" in health-liability due to a lack of explainability suggests a fundamental product-market fit gap in regulated segments.

The Usage Quality Sprint measures *if* they use it; the Commercial Cleanroom measures *if* they buy it. Neither explains *why* the front-line adjusters are reverting to manual notes or why they cannot explain the output to reviewers. The Claim File Review is the only option that provides a "ground truth" audit of the product's actual utility. It allows you to distinguish between a tool that is "accepted" and one that is merely "overridden" or "impossible to explain," preventing you from scaling a feature that provides an illusion of productivity but fails the actual workflow test.

**The strongest reason against it:** It is a slow, manual process that provides a small sample size. In the twelve days before the budget locks, this review will not provide the statistically significant "proof" that a board typically wants to see compared to a quantitative sprint or a commercial test. It risks being dismissed as anecdotal evidence while the executive team is riding a wave of "surprisingly strong" quarterly numbers.

**Observable evidence that would change my mind:** If the "wrong recommendation" tickets in the training channel are found to be purely pedagogical (i.e., users simply don't know which button to click) rather than conceptual (i.e., the recommendation is logically flawed or legally indefensible). If the friction is purely a training issue and not a utility issue, I would pivot to the Usage Quality Sprint.

================  OUT-32  ================

---
anonymous_label: OUT-32
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: bce41d99ab7a7b9fa1462df34ed38e755e02de8790677fc3378aa87cb44c0543
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-32

I recommend that the CEO commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should displace the "scale SignalPath broadly" commitment. Scaling now would be a premature bet on "slop"—success signals that appear strong but are structurally contaminated.

**Why:**
The current perception of the product team as "focused" and "aligned" is a textbook example of the **halo effect** (BK-0048-card-001). Because expansion bookings rose and renewals closed early, the executive team is attributing positive traits (commercial discipline) to the team. However, the evidence suggests these results are driven by a "temporary bundle price" and sales pitches about the *future* roadmap, rather than the actual value of the current product.

Furthermore, your "progress" is currently measured by execution and vanity metrics (usage up 39%, fewer support tickets) rather than **validated learning** (BK-0007-card-001). The usage is driven by managers rerunning samples (not front-line value), and the support ticket drop is a result of tickets moving to a different channel (enablement). Without the Cleanroom, you cannot tell if customers are buying SignalPath or simply buying a discount.

The Commercial Cleanroom is the only option that isolates the performance signal from the pricing/pitch noise, providing the empirical evidence required to determine if you have a viable business or an accounting fluke.

### The Strongest Reason Against
The Commercial Cleanroom creates a short-term risk to the top line. By stopping bundle-price offers and withholding the roadmap pitch, you may see a dip in immediate expansion bookings or slower renewal cycles. In a high-pressure environment with a board meeting in twelve days, the CEO may be reluctant to intentionally "slow down" a winning streak, even if that streak is illusory.

### Evidence That Would Change My Mind
I would change this recommendation if the **Claim File Review** (which you are giving up) revealed that front-line adjusters in the non-regulated segments were accepting and acting on SignalPath suggestions at a rate significantly higher than their manual baseline, *independent* of manager oversight. If the product provides an irreducible utility that users cannot live without, the "bundle price" becomes a secondary acquisition tactic rather than the primary driver of the perceived success.

================  OUT-33  ================

---
anonymous_label: OUT-33
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: c10b17b5a862ebfce1683ee1e671d694c02b3c12987fef9f35e3759876fa725d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-33

I recommend that the CEO commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should displace the "scale SignalPath broadly" commitment. Scaling now would be a premature leap based on "halo-tinted" data and execution metrics that do not prove product-market fit.

**Why:**
The current perception of the product team as "focused" and "commercially disciplined" is a classic instance of the **halo effect** (BK-0048). Because expansion bookings rose and renewals closed early, the executive team is attributing positive traits (alignment, discipline) to the product team. However, the evidence suggests these results are driven by a temporary bundle price and sales pitches about a *future* roadmap, not the current value of SignalPath.

Furthermore, your "progress" is currently measured by usage volume (up 39%) and feature shipment. According to the principle of **validated learning** (BK-0007), these are "vanity numbers" or execution targets that do not prove the product is building a lasting business. The high usage is coming from managers (not front-line adjusters) and the "success" in renewals is entangled with pricing incentives. The Commercial Cleanroom is the only proposed package that isolates the performance signal from the pricing noise, providing empirical evidence of whether customers value SignalPath itself or simply a discounted bundle.

### The Strongest Reason Against
The Commercial Cleanroom creates a short-term risk to the top line. By withholding bundle prices and roadmap pitches from a matched set of accounts, you may intentionally slow down some renewals or lose expansion dollars in the immediate term to gain clarity. This "controlled loss" may be politically difficult to justify to a board that is currently celebrating a "surprisingly strong quarter."

### Observable Evidence That Would Change My Mind
I would change this recommendation if the **Claim File Review** were conducted first and revealed that front-line adjusters in non-regulated segments are accepting and acting on SignalPath suggestions at a high rate without manager intervention. If the "coherent action" (BK-0001) of the adjusters—their actual workflow changes—demonstrates that the product solves a decisive challenge, then the revenue growth is likely a lagging indicator of real value rather than a result of sales engineering. In that case, the risk would shift from "lack of value" to "poor pricing," making a scale-up strategy more viable.

================  OUT-34  ================

---
anonymous_label: OUT-34
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: c2abd009da4ec1485e28a14a6bfb438bef2d28d5fb562777575695a2f6af15d5
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-34

**Recommendation: Run the Commercial Cleanroom.**

The current growth signals are contaminated. The rise in expansion bookings is tied to temporary pricing incentives rather than intrinsic product value, and the positive customer feedback was elicited by sales teams promising future roadmap developments. Because the "success" is currently bundled with financial lures and future promises, you cannot determine if SignalPath is a driver of revenue or merely a passenger to a pricing strategy. The Commercial Cleanroom is the only intervention that isolates the product's actual commercial pull by removing these variables.

**Strongest Reason Against:**
This approach risks short-term revenue. By withholding bundle pricing and roadmap pitches, you may intentionally slow down the current momentum of expansion bookings and extend sales cycles in the immediate term to gain clarity.

**Evidence That Would Change My Mind:**
If you discover that the regional carriers who are already planning to remove SignalPath share a specific operational profile (e.g., they lack the "claims operations managers" who are currently inflating usage stats), I would shift the recommendation to the Claim File Review. This would indicate that the problem is not a lack of commercial demand, but a fundamental failure in the product's utility for the end-user.

================  OUT-35  ================

---
anonymous_label: OUT-35
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: c3e5b77a971db534c316394ff9e2a12b7f05b049b560e204738e845c80e4ef77
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-35

I recommend you commit to the **Claim File Review**.

### The Recommendation
You should advise the CEO to prioritize the Claim File Review over all other options.

Your current "strong quarter" is a lagging indicator driven by sales incentives (bundle pricing) and executive optimism (roadmap pitches), not product-market fit. The core of your business is a B2B workflow tool; therefore, the only metric that matters is whether the software actually solves the problem for the end-user.

The Usage Quality Sprint measures *quantity* (which is currently inflated by managers running samples), and the Commercial Cleanroom measures *willingness to pay* (which is currently skewed by the fear of losing a "centerpiece" feature). Neither tells you **why** front-line adjusters are abandoning the tool after two days or why health-liability users can't justify the output to reviewers.

The Claim File Review is the only option that exposes the "truth" of the workflow. By auditing actual files, you will discover if SignalPath is providing genuine value or if it is simply a "management theater" tool that looks good in a demo but fails in the trenches. This is the only data set that can inform whether you should scale, pivot, or narrow your focus.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and provides a small sample size compared to the automated data of the Usage Quality Sprint or the revenue data of the Commercial Cleanroom. In a high-pressure environment where the board wants to see "scale" and "growth," presenting qualitative findings from a handful of files can seem anemic or overly cautious compared to the "hard numbers" of expansion bookings.

### The Evidence That Would Change My Mind
I would change this recommendation if the "wrong recommendation" tickets in the training channel showed a clear, singular technical bug that—once fixed—immediately restored adjuster usage across all segments. If the friction is a simple UI/UX bug rather than a fundamental failure of the logic or explainability (the "black box" problem in health-liability), then the **Usage Quality Sprint** becomes the superior choice to track the recovery of those users.

================  OUT-36  ================

---
anonymous_label: OUT-36
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: cf997f6c34469e2951c743ae75ae84adc0dc26f954c2fe3db907050868dd32f5
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-36

**Recommendation:** Run the Claim File Review.

**Why:** Your current "strong quarter" is an illusion created by lagging indicators and sales incentives. The expansion bookings are driven by temporary pricing bundles, not proven value, and the usage spike is skewed toward managers performing audits rather than adjusters executing work. Most critically, you have a "silent churn" problem with regional carriers and a fundamental utility failure in the health-liability segment (the inability to explain actions).

The Usage Quality Sprint measures *if* people use the tool, but not *why* they abandon it. The Commercial Cleanroom measures *if* people will pay, but not *what* they are paying for. Only the Claim File Review addresses the "Job to be Done"—whether SignalPath actually improves the claim outcome or creates more work for the adjuster. By identifying where suggestions are overridden or "impossible to explain," you move from measuring vanity metrics (usage %) to measuring product efficacy. This is the only path to determining if SignalPath is a scalable asset or a feature that requires a fundamental pivot before the board locks in next year's budget.

**The strongest reason against it:** This is a slow, qualitative process that provides a small sample size. It does not offer the immediate "statistical" comfort of a dashboard (Usage Quality Sprint) or the direct revenue validation of a price test (Commercial Cleanroom), making it the hardest option to sell to an executive team currently riding a high of "surprising" growth.

**Observable evidence that would change my mind:** If the regional carriers who are removing SignalPath from their contracts explicitly state in writing that their decision is based solely on the removal of the bundle pricing—rather than a lack of utility or inability to justify the tool's output—then the problem is one of pricing strategy rather than product-market fit, making the Commercial Cleanroom the priority.

================  OUT-37  ================

---
anonymous_label: OUT-37
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: d1d512865469eb9486abaaf0d9bf35c189a2450c3593a066446ccd2074554588
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-37

I recommend the **Claim File Review**.

### The Recommendation
You should advise the CEO to commit to the Claim File Review. While the executive team is celebrating a "strong quarter," your data suggests this growth is an illusion created by financial incentives (bundle pricing) and "roadmap selling" rather than actual product-market fit.

The core risk is that you are scaling a "manager's toy"—a tool used for retrospective audits and enablement meetings—rather than an adjuster's utility. The Usage Quality Sprint only tracks *if* they click; the Commercial Cleanroom only tracks *if* they pay. Neither tells you *why* the front-line adjusters are abandoning the tool after two days or why health-liability users can't justify the output.

The Claim File Review is the only option that exposes the "truth" of the workflow: whether SignalPath is actually solving a problem or simply creating a draft that adjusters find too risky or tedious to use. This is the only evidence base strong enough to decide whether to pivot, persevere, or narrow the focus before you lock in next year's budget.

### The Strongest Reason Against It
**It is slow and qualitative.** Unlike the Usage Quality Sprint or the Cleanroom, this does not provide a clean, automated dashboard for the board. It requires manual labor from your team and time from your customers. In a high-pressure environment where the executive team currently feels "aligned" and "disciplined," presenting qualitative evidence that contradicts a 16% rise in bookings may be perceived as "product pessimism" or an attempt to slow down commercial momentum.

### The Observable Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "bundle price" was a negligible driver of renewals (e.g., if 80% of the expansion dollars came from accounts that *did not* receive the discount). If the financial growth is organic and decoupled from the pricing incentive, then the primary risk shifts from "Product Value" to "Pricing Strategy," making the Cleanroom the priority to protect your margins.

================  OUT-38  ================

---
anonymous_label: OUT-38
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: d65ba72385e5aeac4e04c931dc12c3a4bcd743c29d229da0c330bef2172d5cb6
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-38

I recommend the **Claim File Review**.

**Why:**
The current "strong quarter" is built on misleading indicators: expansion revenue was driven by temporary pricing bundles rather than organic value, and usage spikes are coming from managers reviewing closed files (administrative overhead) rather than adjusters managing live claims. Most critically, there is a "silent churn" occurring with regional carriers and a fundamental failure in the regulated health-liability segment due to lack of explainability.

The Usage Quality Sprint only measures *if* they return, and the Commercial Cleanroom only measures *if* they buy. Neither reveals *why* the product is being abandoned or overridden in practice. The Claim File Review provides the only ground-truth data on whether SignalPath is actually solving the problem or simply being "performed" for managers. This evidence is essential to decide if SignalPath requires a pivot in its logic (explainability) or if it is fundamentally flawed before you commit next year's budget to scaling a leaky bucket.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation options. Unlike a dashboard (Sprint) or a sales experiment (Cleanroom), it requires manual auditing of files and interviews with users, which may not provide a statistically significant sample size before the board locks the budget in twelve days.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel show a high correlation with specific, easily fixable UI/UX gaps rather than fundamental logic failures, I would pivot to the **Usage Quality Sprint**. If the data suggested that customers are buying based on the *promise* of the roadmap regardless of current utility, I would pivot to the **Commercial Cleanroom** to test the actual price elasticity and willingness to pay without the bundle.

================  OUT-39  ================

---
anonymous_label: OUT-39
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: dc37befd09495f69916bc8c66e4c535071a9bdc5997a8e53a9466718431da95e
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-39

**Recommendation: Run the Commercial Cleanroom.**

The current growth signals are heavily contaminated. The rise in expansion bookings is tied to temporary pricing bundles, and the positive customer sentiment was elicited by sales teams promising future roadmap items rather than current product value. Because the "success" is currently driven by financial incentives and future promises, you cannot distinguish between a product that creates value and a sales process that creates bookings. The Commercial Cleanroom is the only intervention that isolates the product's actual market pull by removing these artificial stimulants.

**The strongest reason against this:**
This approach risks immediate revenue loss and slower sales cycles in the short term. By removing bundle pricing and roadmap promises, you may see a dip in expansion bookings or longer renewal timelines during the test period, which could create friction with sales leadership and a perceived loss of momentum just as the board is locking the budget.

**Evidence that would change my mind:**
If you discover through an immediate audit of the regional carriers (who are already planning to remove the feature) that their reason for churning is purely a lack of training or a specific missing integration—rather than a failure of the core logic or an inability to justify the action to reviewers—I would pivot to the Claim File Review. If the problem is "how it's used" rather than "whether it's valued," solving for usability is more urgent than validating market demand.

================  OUT-40  ================

---
anonymous_label: OUT-40
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: de58fa47e8ba2bdd01ec8cc6847b9bf6883636b75d4dbae78ef19af11754c16b
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-40

I recommend that you commit to the **Claim File Review**.

### Reasoning: The "Illusion of Growth" Problem
Your current data is suffering from severe **signal contamination**. You have a "strong quarter," but the evidence suggests this is driven by sales incentives (bundle pricing) and managerial vanity (ops managers running samples for meetings), rather than genuine product-market fit with the end user (the adjuster).

The most alarming data point is the behavior of front-line adjusters: they use the tool for two days and then revert to manual notes. This indicates that SignalPath is likely perceived as a "management surveillance tool" or a "suggestion engine" that adds friction rather than reducing it. In B2B workflow software, if the end-user abandons the tool, the renewal is a ticking time bomb—regardless of what the buyer says during a bundle-discounted renewal window.

Here is why the other options are insufficient:
*   **Scale SignalPath Broadly:** This is high-risk. You are scaling a product that regional carriers are already planning to remove and adjusters are abandoning.
*   **Usage Quality Sprint:** This measures *quantity* of activity, not *quality* of outcome. You already know usage is up; you just don't know if that usage is productive or performative.
*   **Commercial Cleanroom:** This tests the *pricing/packaging* strategy, not the *product value*. It tells you if people will pay for it without a discount, but it doesn't tell you how to fix the product so they *want* to pay for it.
*   **Narrow to Health-Liability:** This is a premature pivot based on one segment's struggle with explainability. You don't yet know if the core value proposition is broken for everyone or just inhibited by regulation in one sector.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move from *proxy metrics* (clicks and tickets) to *outcome metrics* (accepted vs. overridden suggestions). This will tell you if the product is actually solving the problem or if your "strong quarter" is simply a result of aggressive sales engineering.

### The Trade-off
By choosing the Claim File Review, you are displacing the **Usage Quality Sprint**. You give up the ability to track real-time behavioral trends across the entire install base in exchange for a deep, forensic understanding of why the product is failing or succeeding at the desk level. You are sacrificing *breadth* for *depth*.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. In twelve days, the board wants a budget for "scaling" or "pivoting." A file review provides a diagnosis, not a growth engine. The CEO may find this approach too passive or "academic" when the sales team is currently reporting a winning streak. There is a risk that by focusing on the "broken" parts of the workflow, you dampen the commercial momentum created by the sales team.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you could prove that the "abandonment" by adjusters is a training issue rather than a utility issue.

Specifically, if you found evidence that adjusters who received high-touch enablement continued to use SignalPath at a rate of >60% after the first month, then the product is sound and the problem is purely GTM/Enablement. In that case, testing the commercial viability (the Cleanroom) becomes the priority to ensure you aren't just "buying" growth with discounts.

================  OUT-41  ================

---
anonymous_label: OUT-41
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: e091f6a04b62ad47e2c37d4f8b917a8031a48808f053bbf32734df40784ddb6a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-41

**Recommendation:** Commit to the **Claim File Review**.

**Why:** Harbor Claims is currently suffering from a "Halo Effect," where positive lagging indicators (expansion bookings, early renewals) are being attributed to the product’s value when they may actually be driven by temporary pricing bundles and sales narratives.

The evidence suggests a critical gap between *perceived* value (at the buyer/manager level) and *actual* utility (at the adjuster level). The "enthusiastic comments" are coming from buyers told SignalPath is the roadmap centerpiece, while front-line users—the ones who actually drive long-term retention—are abandoning the tool or using it only under managerial surveillance. The Usage Quality Sprint is too superficial (tracking events doesn't explain *why* a plan was ignored), and the Commercial Cleanroom is too risky (it tests pricing/sales tactics rather than product-market fit). The Claim File Review is the only option that provides "ground truth" by auditing whether the software's core output—the next-action plan—is actually correct, usable, and explainable. This is the only way to determine if SignalPath is a scalable asset or a "leaky bucket" that will cause massive churn once the bundle pricing expires and procurement windows close.

**The strongest reason against it:** It is a slow, manual process that provides a small sample size. While the board wants budget certainty in twelve days, this review will not provide a statistically significant "green light" for scaling across the entire customer base in that timeframe, potentially delaying aggressive growth targets.

**Observable evidence that would change my mind:** If the "regional carrier" churn (the two accounts already planning to remove SignalPath) was revealed to be caused exclusively by a known, trivial technical bug or a specific missing integration—rather than a failure of the tool's logic or explainability—I would pivot to the **Usage Quality Sprint** to accelerate scaling.

================  OUT-42  ================

---
anonymous_label: OUT-42
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: e4aca9a08d57588d41630c8257e2a4df0b916dd3af98942a543a4faa38a2a896
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-42

I recommend the **Claim File Review**.

### The Recommendation
You should commit to the Claim File Review. While the executive team is celebrating "commercial discipline" and growth, your data suggests you are currently experiencing a **false positive**.

The expansion bookings are skewed by temporary pricing (financial incentive, not value incentive), and the usage spikes are driven by managers auditing the past rather than adjusters executing the present. Most critically, the "drop-off" behavior among front-line adjusters and the "explainability" gap in health-liability claims indicate a fundamental failure in the product’s core value proposition: trust.

The Claim File Review is the only option that bypasses "noisy" metrics (like event tracking or skewed sales cycles) and looks at the ground truth: **Did the software actually move the claim forward, or did a human have to fix it?** This will tell you if SignalPath is a productivity tool or merely an "enablement prop" that managers like but adjusters find burdensome.

### The Strongest Reason Against It
The Claim File Review is slow and qualitative; it provides a "snapshot" rather than a "stream." By the time you finish reviewing these files, the board budget will be locked. Unlike the Usage Quality Sprint (which provides a dashboard) or the Commercial Cleanroom (which tests price elasticity), the File Review does not provide a quantitative "win/loss" metric that Sales or Finance can easily digest. You risk appearing to move too slowly while the executive team is in a "growth" mindset.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the regional carriers removing SignalPath from their contracts are "outliers" (e.g., they have unique legacy tech stacks) and that the national-broker accounts are renewing *specifically* because of SignalPath, regardless of the bundle pricing. If the "willingness to pay" is decoupled from the discount and tied strictly to the feature, the problem shifts from a **Value Problem** (which requires a File Review) to a **Pricing/Packaging Problem** (which requires the Cleanroom).

================  OUT-43  ================

---
anonymous_label: OUT-43
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: e9f1ae0f0fff348f73fd8ab4ab83b1b3233ee6bb440619cf58096b6f77c09023
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-43

**Recommendation: Run the Claim File Review.**

The current growth signals are contaminated. Expansion revenue is tied to temporary pricing incentives rather than perceived value, and positive customer sentiment was solicited by sales teams promising future roadmap developments. Usage data is misleading because it captures retrospective manager audits rather than active adjuster workflow. The Claim File Review is the only intervention that isolates independent evidence by analyzing actual claim outcomes and overrides, bypassing both sales incentives and vanity usage metrics. It reveals whether the product is providing a functional utility or if it is being bypassed by the end-user.

**Strongest Reason Against:**
This approach ignores the immediate commercial risk of the "bundle price" bubble. By focusing on file quality rather than the Commercial Cleanroom, you risk committing to a product strategy for next year based on technical viability while remaining blind to whether the market will actually pay for the feature without heavy discounting or roadmap promises.

**Evidence that would change this recommendation:**
If the regional carriers who are removing SignalPath provide documented evidence that their decision is based on a lack of "explainability" for reviewers (similar to the health-liability segment) rather than a lack of general utility, I would instead recommend narrowing the company plan around regulated health-liability workflows. This would shift the priority from validating general utility to solving a specific, systemic blocker that is already causing known churn.

================  OUT-44  ================

---
anonymous_label: OUT-44
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: ef33b714e534ac90c0e8e29d2e35b9658c454fcc2ff37bf5c0fd4d70b1a220eb
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-44

### Recommendation: Run the Claim File Review

I recommend you commit to the **Claim File Review**.

#### Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (expansion bookings, renewals) are being skewed by pricing incentives and sales narratives, while your leading indicators (usage) are being skewed by "vanity" activity from managers rather than utility for the end-user.

The most dangerous signal in your data is the **behavioral decay** of front-line adjusters (heavy use for two days, then abandonment) and the **explainability gap** in health-liability. This suggests that SignalPath may be "demo-ware"—impressive to a buyer or a manager, but friction-heavy for the practitioner.

Here is why the other options are insufficient or risky:
*   **Scale Broadly:** This is reckless. You have evidence of silent churn (the regional carriers) and a lack of product-market fit in regulated segments. Scaling now would likely increase churn in 6–12 months.
*   **Usage Quality Sprint:** This measures *if* people are using it, but not *why* they stop. You already know the return rate is low; more dashboards won't tell you if the recommendations are wrong or simply unexplainable to a reviewer.
*   **Commercial Cleanroom:** This tests the *sales pitch*, not the *product*. If you find that buyers don't buy without the roadmap pitch, you still won't know if the product actually solves the problem once installed.
*   **Narrow to Health-Liability:** This is a premature pivot. You have evidence that this segment specifically struggles with the product; narrowing your focus to the most difficult segment before fixing the core utility is a strategic error.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move from *quantitative* usage (which is currently misleading) to *qualitative* utility. You will discover if the "abandonment" is due to bad logic, poor UI, or regulatory constraints. This is the only data set that can inform whether you need to pivot the product's logic or simply improve the enablement.

#### The Trade-offs
By choosing the Claim File Review, you are sacrificing **speed of commercial validation**. You will not have a "clean" sales experiment (the Cleanroom) to tell the board exactly how much revenue is tied to the bundle pricing. You are accepting a period of uncertainty regarding the immediate quarterly bookings in exchange for certainty regarding long-term product viability.

#### The Strongest Reason Against This Recommendation
The Claim File Review is slow and manually intensive. In a high-pressure environment with a board deadline in twelve days, the executive team may perceive this as "academic" or "too slow." It does not provide a binary "yes/no" on revenue growth for the next quarter; it provides a diagnosis of product health. There is a risk that by the time the review is complete, you have missed the window to adjust your sales strategy for the upcoming renewal cycle.

#### Observable Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "silent churn" from the regional carriers was not due to product utility, but specifically due to a pricing misalignment (e.g., they love the tool but find the bundle price structure offensive). If the problem is *pricing* rather than *product-market fit*, diagnosing the file utility is a waste of time; you would need to fix the commercial model immediately to stop the bleeding.

================  OUT-45  ================

---
anonymous_label: OUT-45
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: f736cee779da2c710175a6ebcc77bd42f41e7b3ed9715e99d45f59cc0dfdf63d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-45

### Recommendation: The Claim File Review

You should recommend the **Claim File Review**.

#### Reasoning
Your current situation is a "false positive" trap. The executive team sees strong financial signals (expansion bookings, shortened sales cycles) and high usage numbers (+39%). However, the underlying data suggests these are lagging indicators or vanity metrics:
1. **Financials are distorted:** Expansion is driven by temporary bundling/pricing incentives, not necessarily value realization.
2. **Usage is misleading:** The growth is driven by managers (training/auditing) rather than the end-users (adjusters).
3. **Retention is fragile:** Front-line adjusters are abandoning the tool after two days, and regional carriers are already planning to cut it.

The core problem is a **lack of evidence regarding "Job-to-be-Done" completion.** You do not know if SignalPath actually improves the claim outcome or if it is simply a "theatre of productivity" that managers like but adjusters find useless or risky (especially in regulated health-liability).

The other options fail to address this:
* **Scaling Broadly** is premature and risks a massive churn event in 12 months.
* **Usage Quality Sprint** measures *that* people are using it, but not *why* or if the output is correct. It tracks behavior, not value.
* **Commercial Cleanroom** tests price elasticity and sales narratives, but it doesn't fix the product. If the product is broken, a cleanroom just confirms you can't sell it without bribes; it doesn't tell you how to fix the workflow.
* **Narrowing to Health-Liability** is a premature pivot based on one segment's struggle, without knowing if the struggle is a solvable UX issue or a fundamental product failure.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. overridden suggestions). This tells you exactly where the product is failing: Is it a lack of trust? A lack of explainability? Or simply wrong advice?

#### The Tradeoffs
By choosing the Claim File Review, you are sacrificing **speed of commercial validation.** You are telling the CEO that you cannot yet guarantee the "expansion" trend is real or sustainable. You are effectively pausing the aggressive sales momentum to ensure you aren't building a "leaky bucket."

#### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. While you are spending weeks reviewing files, the sales team may lose momentum, and the board may perceive a "loss of confidence" in a feature that they currently believe is a home run. It is the least "exciting" option for an executive team riding a high from a strong quarter.

#### Observable Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "abandonment" by adjusters was not due to product failure, but due to a **lack of mandate.**

If the Claim File Review reveals that the suggestions are actually accurate and helpful, but adjusters simply aren't *required* to use them by their bosses, the problem is no longer a product/value problem—it is a pricing and packaging problem. In that case, you don't need to fix the software; you need to change how it is sold and positioned (the Cleanroom) to ensure it is tied to a corporate mandate rather than an adjuster's preference.

================  OUT-46  ================

---
anonymous_label: OUT-46
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: f80ffbfd0ace24b62d4cb88fa746560e3fec34513f515b2cc260462e591c4f53
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-46

I recommend that you commit to the **Claim File Review**.

**Why:**
Your current "strong quarter" is an illusion created by lagging indicators and sales incentives. Expansion bookings were driven by temporary pricing bundles, not necessarily value realization; usage is inflated by managers running samples rather than adjusters working live files; and the "reduction" in support tickets is merely a migration of complaints to a different channel.

The most critical risk is the "explainability" gap in the regulated health-liability segment and the silent churn of regional carriers. You do not have a scaling problem or a pricing problem; you have a fundamental uncertainty about whether the product's output is actually useful or actionable for the end-user. The Claim File Review is the only proposal that provides a ground-truth audit of *why* plans are being overridden or abandoned, allowing you to fix the product before you scale a flawed version or lock in a roadmap based on "enthusiastic" but superficial sales feedback.

**The strongest reason against it:**
It is a slow, manual process that provides a small sample size. Unlike the Usage Quality Sprint (which gives you broad quantitative trends) or the Commercial Cleanroom (which tests immediate revenue elasticity), a file review is labor-intensive and may not provide the statistically significant "proof" the board wants to see in twelve days to justify a massive budget shift.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" results showed that buyers were willing to pay full price for SignalPath *without* the roadmap pitch or bundle discounts, it would suggest that the perceived value is high enough to override current usage frictions. In that case, I would shift the recommendation to scaling broadly, as the market demand would be outweighing the current operational inefficiencies.

================  OUT-47  ================

---
anonymous_label: OUT-47
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: fbf3cf6b5e804dfef7af3597c5f1a0dffa243ca3a11c0e14f02bf351e2eaf1f2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-47

I recommend that you commit to the **Claim File Review**.

**Why:**
Your current "strong quarter" is an illusion created by lagging indicators and sales incentives. The expansion bookings are skewed by temporary bundle pricing, and the usage spike is driven by managers performing retrospective audits rather than adjusters using the tool in live workflows. Most critically, you have a "black box" problem: adjusters in regulated segments are abandoning the tool because they cannot explain its logic to reviewers.

The Usage Quality Sprint measures *that* people are using the tool, and the Commercial Cleanroom measures *if* they will pay for it, but neither tells you *why* the tool is failing at the point of execution. The Claim File Review is the only option that provides a ground-truth audit of whether SignalPath’s output is actually accurate, actionable, or explainable. Before scaling or narrowing the product, you must determine if the "wrong recommendation" tickets have actually decreased or simply migrated to a different support channel.

**The strongest reason against it:**
It is a slow, manual process that provides a small sample size. Unlike the Usage Quality Sprint, it will not give you a real-time dashboard of behavior across your entire install base, and unlike the Commercial Cleanroom, it does not provide immediate evidence of price elasticity or "will-to-pay."

**Observable evidence that would change my mind:**
If the data from the "training channel" (where enablement requests are now tagged) reveals that adjusters aren't struggling with the *logic* of the recommendations, but are simply lacking a technical "how-to" guide for the interface. If the friction is purely operational/educational rather than a fundamental failure of the product's output, I would pivot to the Usage Quality Sprint to optimize enablement.

================  OUT-48  ================

---
anonymous_label: OUT-48
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: fd9e80c82d53d8b896dbd958dc24fe315d3aab00bd58c5e3f39244c884d37c3a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-48

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is "entangled," meaning your lagging indicators (bookings, renewals) are likely being driven by sales incentives (bundle pricing) and executive optimism rather than product-market fit. The usage data is equally deceptive: high volume is driven by managers (non-users) and initial novelty, while the core user (the adjuster) is abandoning the tool due to a fundamental "explainability" gap in regulated segments.

The Usage Quality Sprint measures *if* they use it, and the Commercial Cleanroom measures *if* they will pay for it, but neither explains *why* the product is failing the adjuster's workflow. Before scaling or narrowing the market, you must determine if SignalPath is providing actual utility (accepted suggestions) or merely "noise" that managers find useful for reporting. The Claim File Review is the only option that audits the actual work product to distinguish between a "sold" feature and a "solved" problem.

**Strongest Reason Against:** This is the slowest, most manual path to an answer. Unlike a dashboard (Sprint) or a sales test (Cleanroom), this requires qualitative labor and manual auditing of files. In a twelve-day window to lock the budget, this approach provides the least "immediate" data for a board presentation and risks being viewed as too academic compared to hard revenue metrics.

**Evidence that would change my mind:** If the "Commercial Cleanroom" results were to show that customers are renewing and expanding at the same rate *without* the SignalPath pitch or bundle pricing. That would indicate that the company's overall value proposition is so strong that SignalPath’s specific utility is secondary to the platform's general existence, making a deep-dive file review an unnecessary distraction from broader scaling.
